Analyst consensus

As at 8 August 2022

FY22

 

Low

High

Average (Mean)

Revenue (£m)

1,141.9

1,228.0

1,176.5

EBITDA (£m)

211.2

218.0

215.0

EBIT (£m)

109.7

116.9

113.5

PBT (£m)

20.0

29.8

24.3

Net income (£m)

16.0

22.0

18.8

Adjusted EPS (p)

4.1

5.4

4.6

Net bank debt (£m)

(256.0)

(179.0)

(213.8)

Net debt (including lease liabilities) (£m)

(1,074.5)

(1,030.0)

(1,052.0)

FY23

 

Low

High

Average (Mean)

Revenue (£m)

1,184.1

1,312.0

1,248.0

EBITDA (£m)

232.0

253.0

242.1

EBIT (£m)

132.0

144.6

137.9

PBT (£m)

43.9

55.3

48.5

Net income (£m)

33.4

39.5

36.6

Adjusted EPS (p)

8.3

9.8

9.0

Net bank debt (£m)

(231.0)

(119.0)

(177.6)

Net debt (including lease liabilities) (£m)

(1,053.7)

(983.0)

(1,016.3)

 

The figures shown above are on an adjusted, post IFRS 16 basis. They include estimates from seven analysts at the following institutions who have updated their estimates following Spire Healthcare’s FY21 results: Numis, JP Morgan, Barclays, Berenberg, Jefferies, Peel Hunt and RBC.